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patients,	 22.2%	 were	 found	 to	 have	 psychotic	 symptoms,	 of	 whom	 70%	 had	







uses	 of	 the	 currently	 available	 atypical	 APDs	 in	 this	 patient	 population	 are	 often	
complicated	by	ADRs.	The	selective	5-	HT2A	inverse	agonist,	pimavanserin,	could	be	a	
better	alternative	in	the	treatment	of	PDP.
K E Y W O R D S
adverse	drug	reactions,	antipsychotics,	Parkinson’s	disease,	Parkinson’s	disease	psychosis
1  | INTRODUCTION
Parkinson’s	 disease	 (PD)	 is	 a	 slowly	 progressive	 neurodegener-
ative	 disease	 that	 affects	 7–10	 million	 people	 worldwide	 and	
is	 more	 common	 in	 older	 people.	 The	 number	 of	 PD	 patients	 is	
expected	 to	 increase	 in	 parallel	 to	 the	 rising	 age	 of	 our	 popula-
tion.	 PD	 is	 characterized	 by	 a	 progressive	 loss	 of	motor	 function	
and	 a	 wide	 spectrum	 of	 nonmotor	 symptoms	 (NMSs).	 NMSs	 in	
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PD	 have	 been	 systematically	 described	 and	 include	 a	 high	 prev-
alence	 of	 neuropsychiatric	 symptoms,	 such	 as	 psychosis,	 depres-
sion,	 cognitive	 	impairment,	 and	 sleep	 disturbances	 (Munhoz,	





greater	 likelihood	 of	 placement	 in	 nursing	 homes	 and	 increased	
mortality.
PDP	 is	 characterized	by	hallucinations	 (particularly	visual),	 delu-
sions,	 illusions	 and	 false	 sense	 of	 presence.	The	 etiology	 of	 PDP	 is	
thought	 to	 be	multifactorial.	 Some	 studies	 show	 that	 the	 develop-
ment	of	PDP	is	associated	with	the	use	of	dopaminergic	medications	
(Bizzarri	 et	al.,	 2015).	 However,	 other	 studies	 suggest	 medications	
alone	cannot	explain	emergence	of	psychosis	(including	no	dose	rela-




development	 of	PDP	 (Gama	et	al.,	 2015;	Zhu,	van	Hilten,	 Putter,	&	
Marinus,	2013).
What	is	also	noteworthy	is	that	the	pathophysiology	of	PDP	is	
most	 likely	 attributed	 to	 disorders	 of	 the	 cholinergic	 and	 seroto-
nergic	systems	(Mocci	et	al.,	2014;	Rolland	et	al.,	2014)	as	well	as	
to	changes	 in	brain	structure	 (Kiferle	et	al.,	2014).	With	 regard	 to	
therapeutics,	PDP	can	be	difficult	to	treat	due	to	the	 lack	of	safe,	
effective	pharmacological	treatments.	The	first-	line	strategy	in	the	
treatment	 of	 persistent	 and	 problematic	 PDP	 is	 represented	 by	
reduction	 in	 anti-	PD	 medications.	 However	 due	 to	 different	 and	










The	 search	 for	 effective	 strategies	 for	 the	 treatment	 of	
PDP	has	been	 an	 area	 of	 much	 interest.	 The	 only	 drug	 with	
	confirmed	 benefit	 without	 worsening	 Parkinsonism	 has	
been	clozapine	 (Seppi	et	al.,	 2011).	 However	 the	 avoidance	
of	 clozapine	 in	 large	 part	 due	 to	 the	 inconvenience	 of	 frequent	
blood	 testing	 (Hack	 et	al.,	 2014).	 Additionally,	 patients	 and	 pro-
viders	must	both	be	 registered	with	 the	FDA	 for	clozapine	 to	be	




10	years	 in	 an	 outpatient	 specialty	 clinic	 and	 their	 adverse	 drug	
reactions	(ADRs).




2015.	 Because	 data	 were	 collected	 retrospectively	 from	 records	
and	the	identity	of	patients	was	not	obtained,	informed	consent	was	
not	 required.	After	 reviewing	each	patient’s	 EMR,	 all	 patients	were	
screened	for	a	diagnosis	of	 iPD	with	supportive	features	on	a	com-
plete	 neurological	 examination	 including	muscle	 tone,	 posture,	 gait	
and	 involuntary	 movement.	 Besides,	 iPD	 patients	 with	 incomplete	
records	and/	or	with	psychotic	symptoms	attributable	to	other	condi-
tions	were	excluded.	Demographic	variables	 collected	 included	 sex,	
age	range,	and	age	at	onset	of	PD	and	age	at	onset	of	PDP.	Clinical	
variables	include	antiparkinsonian	treatment,	APD	use	and	ADRs,	and	






Data	were	 reported	 as	 simple	 statistics,	 including	 number,	 per-
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hallucination	 reported	among	our	cohort	were	visual	hallucinations.	
Descriptions	of	visual	hallucinations	 included	seeing	people	and	fire	





symptoms	 occurred	 up	 to	 several	 times	 per	 day	 and	 mostly	 while	
alone,	or	in	a	quiet	environment.
In	our	 report,	 there	were	46.7%	 iPD	patients	exposed	 to	L-	dopa	
monotherapy	and	23.8%	of	these	patients	were	reported	to	develop	
PDP.	Of	those	taking	L-	dopa	and	dopamine	agonist	therapy	together,	
28.6%	developed	 psychosis.	Twenty-	five	 percent	 reported	 onset	 of	
psychosis	 during	 dopamine	 agonist	 therapy	 alone	(Table	2).	None	 of	
the	six	patients	on	nondopaminergic	drugs	for	PD	developed	psychosis.
Psychotic	 symptoms	 mainly	 occurred	 ten	 or	 more	 years	 after	
the	diagnosis	of	 iPD.	Psychotic	symptoms	were	observed	 in	10%	of	
patients	 within	 5	years	 of	 diagnosis	 and	 in	 80%	 of	 patients	 within	









chotic	 symptoms.	 Two	 patients	were	 treated	with	 risperidone:	 one	
received	 risperidone	 monotherapy,	 whereas	 the	 other	 patient	 was	
treated	 with	 quetiapine	 initially,	 and	 then	 switched	 to	 risperidone.	
Both	 experienced	 alleviation	 of	 psychotic	 symptoms.	 However,	 all	
atypical	APDs	used	were	associated	with	ADRs	 (Table	4).	Both	que-
tiapine	 and	 olanzapine	 could	 cause	 sedation	 and	 sialorrhea;	 both	
olanzapine	and	risperidone	resulted	in	worsening	of	motor	symptoms.	
The	daily	dose	range	of	quetiapine,	olanzapine,	and	risperidone	was	
25	mg/day–150	mg/day,	 2.5	mg/day–5	mg/day,	 and	 1	mg/day,	
respectively	(Table	4).
4  | DISCUSSION
With	 a	 shift	 in	 our	 understanding	 of	 Parkinson’s	 disease	 over	 the	
past	two	decades,	we	have	developed	a	greater	appreciation	for	the	















longitudinal	 analyses	 of	 follow-	up	 data	 (Fernandez,	 Lapane,	 Ott,	 &	
Friedman,	2000),	 there	 is	no	consensus	whether	men	or	women	are	
more	likely	to	suffer	from	PDP.	After	all,	our	samples	are	small.
Important	 risk	 factors	 associated	with	 the	 development	 of	 psy-
chotic	 symptoms	 in	 iPD	are	older	 age,	 sex,	 longer	disease	duration,	
and	severity.	Additionally,	previous	studies	have	identified	that	dopa-




Antiparkinsonian drugs Number of iPD Number of PDP Percentage (%)
L-	dopa	monotherapy 21 5 23.8













Total, n (%)<5 [5–10] [10–15] >15
Male	(n) 1 2 3 0 6	(60)
Female	(n) 0 0 2 2 4	(40)
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study,	we	 observed	 that	 the	 combination	 of	L-	dopa	with	 dopamine	








atypical	 antipsychotic	 for	PDP,	with	findings	 to	 support	 therapeutic	
benefit	 without	 worsening	 of	 motor	 function.	 Despite	 its	 demon-
strated	 efficacy,	 subsequent	 studies	 have	 shown	 that	 clozapine	 has	
potentially	 fatal	 agranulocytosis	 (requiring	 frequent	 blood	 testing)	
and	myocarditis,	 in	 addition	 to	 relatively	milder	 side	 effects	 includ-








Quetiapine,	 another	 first-	line	 treatment	 for	 PDP,	 is	 similar	 to	








Besides,	 there	 is	 insufficient	evidence	for	the	efficacy	of	quetiapine.	
Several	randomized	clinical	trials	demonstrated	no	change	in	psychotic	
outcomes	 with	 quetiapine	 (Lertxundi	 et	al.,	 2015;	 Prohorov,	 Klein,	
Miniovitz,	Dobronevsky,	&	Rabey,	2006).	In	our	current	report,	there	






Two	 additional	 atypical	 APDs	 used	 in	 PDP	 are	 olanzapine	 and	
risperidone.	Most	 studies	 reported	 olanzapine	 can	 lead	 to	 intolera-
ble	motor	deterioration	even	at	 low	doses	 (Fernandez,	Trieschmann,	
&	 Friedman,	 2003).	Our	 findings	 are	 consistent	with	 these	 findings	
from	previous	studies.	Moreover,	 it	 is	remarkable	that	an	analysis	of	
the	 Spanish	 Pharmacovigilance	 Database	 indicated	 olanzapine	 also	
could	produce	NMS	in	PDP	patients;	likewise,	risperidone	can	dramat-
ically	aggravate	motor	function	in	some	PD	patients	(Lertxundi	et	al.,	
2015).	 Consequently,	 the	 American	 Academy	 of	 Neurology	 (AAN)	
does	not	recommend	these	two	drugs	for	the	treatment	of	PDP.	In	our	











PDP	 remains	 a	 significant	 therapeutic	 challenge.	 The	 therapeutic	




















The	 behavioral	 effects	 of	 pimavanserin	 (formerly	 ACP-	103)	 are	
similar	 to	 those	 of	 atypical	 APDs	 like	 quetiapine,	 olanzapine	 and	
risperidone,	which	have	appreciable	antagonist	activities	at	5-	HT2A	
receptors.	 However,	 unlike	 the	 atypical	 APDs,	 pimavanserin	 lacks	
DA	D2	antagonist	activity	and	thus	does	not	have	the	same	delete-
rious	effect	on	dopamine	replacement	therapy	and	does	not	worsen	








Quetiapine 7 25–150 Sedation,	
sialorrhea
Olanzapine 2 2.5–5 Motor	worsening,	
sedation,	
sialorrhea
Risperidone 2 1 Motor	worsening
iPD,	idopathic	Parkinson’s	disease;	PDP,	Parkinson’s	disease	psychosis;	SD,	
standard	 deviation;	 ADRs,	 adverse	 drug	 reactions;	 APDs,	 Antipsychotic	
drugs.
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interesting	 to	 note	 that	 pimavanserin	 has	 some	 unique	 pharmaco-





An	 animal	 model	 of	 PD	 showed	 that	 pimavanserin	 not	 only	
reversed	the	psychotic	behaviors,	but	did	so	without	worsening	motor	


















serin	may	 complement	 or	 even	 replace	 current	 available	 treatment.	
NUPLAZID™	(pimavanserin)	has	been	approved	by	the	U.S.	Food	and	
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